PINK1 and type 2 diabetes mellitus: Pioglitazone, an anti-diabetic drug for Type 2 diabetes mellitus (T2DM) under the category of thiazolidinediones (TZDs), increases PINK1 expression via NF-κB activation and enhances mitophagy.